Steven D. Gore MD

Director of Hematologic Malignancies

Departments & Organizations

Office of Student ResearchCancer Center, Yale: Hematology Program; Developmental TherapeuticsHematology

Research Interests

Clinical trials for patients with leukemia and meylodysplastic syndromes with a focus on translational research. Mechanism behind the clinical activity of drugs which putatively target epigenetic dysregulation. more...


  • M.D., Yale University School of Medicine, 1984

Selected Publications

  • Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res. 2014 Mar 1;20(5):1249-58. PMID 24423613
  • Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS.Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. J. Clinical Oncology 2014 Apr 20;32(12):1242-8. PMID 24663049
  • Gore, S.D., Fenaux, P., Santini, V., Bennett, J.M., Silverman, L.R., Seymour, J.F., Hellstrom-Lindberg, E., Swern, A.S., Beach, C.L., List, A.F. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013 Jul; 98(7):1067-72. PMID: 23585522



Latest News


Edit Profile